The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00000661|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : August 4, 2008
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Oxazepam Drug: Zidovudine||Phase 1|
Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. This study is important because of the potential for toxicity resulting from a reaction between AZT and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with HIV infection.
Patients are studied to determine oral and intravenous AZT and single oral dose oxazepam pharmacokinetics. Patients then take AZT and oxazepam together to determine if interactions between the drugs occur.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||8 participants|
|Masking:||None (Open Label)|
|Official Title:||The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000661
|United States, California|
|Palo Alto Veterans Adm Med Ctr / Stanford Univ|
|Palo Alto, California, United States, 94304|
|Study Chair:||Israelski D|
|Study Chair:||Blaschke T|